NCT01446133View on ClinicalTrials.gov

Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

December 12, 2011

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions

LeukemiaLymphoma

Interventions

DRUG

Rituximab

375 mg/m2 by vein on Day 1, Day 8, Day 15 and Day 22 and then continued once every 4 weeks during cycles 3-12 (+ 7 days). Rituximab will not be given in Cycle 2.

DRUG

Lenalidomide

10 mg/day by mouth daily beginning on Day 9 of cycle 1.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston